On behalf of the Editorial Board of the World Journal of Urology, we extend our warmest wishes for a Merry Christmas and a Happy New Year. May the coming year bring health, peace, and continued scientific progress.
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC)
https://t.co/A3aECDJyZg
In patients with BCG-naive, high-risk non-muscle-invasive #BladderCancer (NMIBC), recurrence and progression after standard transurethral resection of bladder tumor (TURBT) and BCG therapy remain significant challenges.
This phase 3, randomized, open-label trial evaluated whether adding 1 year of durvalumab to BCG therapy could improve outcomes compared with BCG alone. A total of 1,018 patients were randomized to durvalumab plus BCG induction and maintenance, durvalumab plus BCG induction only, or BCG induction and maintenance alone. At a median follow-up of approximately 5⃣ years, the combination of durvalumab with BCG induction and maintenance reduced the risk of disease recurrence or death by 32% compared with BCG alone (hazard ratio 0.68), with a manageable safety profile.
These findings suggest that durvalumab combined with BCG induction and maintenance may offer a new, effective treatment option for patients with high-risk NMIBC.
@mdesantis234@joanfundi@DrFelixGuerrero@docjavip@tompowles1@BigotP
@Ugobernalicis@ALeaument Champs de Martyrs à Saint Florent de Viel. 2000 femmes, enfants et hommes fusillés. Populicide commandité par Robespierre. Un exemple parmi d’autres… comment peut-on célébrer cela?!
Excited to share results from our French national UroCCR network regarding racial disparities in RCC, with black patients showing highly likelihood for presenting rare variants of RCC. Thanks for @uroccr collaborators and team #CARARE#icans@kidneycan@kcCURE@BigotP
Fantastic success for the @AFUrologie and #GETUG@ASCO American Society of Clinical Oncology (ASCO) society #GU25 with the release of the first data phase 2 trial about neo adjuvant systemic combo treatment of chemotherapy and immunotherapy before radical nephroureterectomy.
• 50 patients included over 3 years in 10 French centers.
• Feasibility: confirmed.
• Tolerance: no grade 3/4 adverse events related to immunotherapy.
• Response: 13% pT0 and 50% <pT1 in the cisplatin arm.
These data are displayed in a simultaneous publication of this trial in the Journal of Clinical Oncology
https://t.co/JUxa1J9WL6 @JCO_ASCO
Let's keep moving forward to the Phase III 🤓
@HouedeN@FAudenet@Neuzillet@amassonlecomte@evanguelosx@delataillealex@pouessel@ThierryCheval@laconss@ChristineAbraha@Glulu80@Uroweb@afufuro
#eauguidelines
💙 #NovembreBleu 💙 || Campagne de dépistage pour les hospitaliers #CancersMasculins👨⚕️
🗓 𝗗𝗲𝘀 𝗰𝗿𝗲́𝗻𝗲𝗮𝘂𝘅 𝘀𝗼𝗻𝘁 𝗱𝗶𝘀𝗽𝗼𝗻𝗶𝗯𝗹𝗲𝘀 𝗱𝗲̀𝘀 𝗹𝗲 𝗹𝘂𝗻𝗱𝗶 𝟰 𝗻𝗼𝘃𝗲𝗺𝗯𝗿𝗲, 𝗱𝗲 𝟵𝗵 𝗮̀ 𝟭𝟮𝗵 ❗
🖥️ Toutes les infos sur l'intranet du #CHUAngers
📢 Nouvelle Actualité!
Félicitations au Dr Mark Purdue du National Cancer Institute (NCI) pour la parution dans Nature Genetics.(UroCCR n°53)👏
▶️Retrouvez l'intégralité de l'article sur le site d'UroCCR :https://t.co/0ALzdINgFg
#kidneycancer#urology#research#genes#cancer
Happy to see our @uroccr NEPRAH study published in European Urology Oncology @eurouroonc
@CCAFU@AFU@AlexIngels@UrologieMondor
https://t.co/BXTY9eG4WP
29 🇫🇷 French centers
3451 Patients included